These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37693537)

  • 1. Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy.
    Kim AE; Lou KW; Giobbie-Hurder A; Chang K; Gidwani M; Hoebel K; Patel JB; Cleveland MC; Singh P; Bridge CP; Ahmed SR; Bearce BA; Liu W; Fuster-Garcia E; Lee EQ; Lin NU; Overmoyer B; Wen PY; Nayak L; Cohen JV; Dietrich J; Eichler A; Heist R; Krop I; Lawrence D; Ligibel J; Tolaney S; Mayer E; Winer E; Perrino CM; Summers EJ; Mahar M; Oh K; Shih HA; Cahill DP; Rosen BR; Yen YF; Kalpathy-Cramer J; Martinez-Lage M; Sullivan RJ; Brastianos PK; Emblem KE; Gerstner ER
    bioRxiv; 2023 Aug; ():. PubMed ID: 37693537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.
    Kim AE; Lou KW; Giobbie-Hurder A; Chang K; Gidwani M; Hoebel K; Patel JB; Cleveland MC; Singh P; Bridge CP; Ahmed SR; Bearce BA; Liu W; Fuster-Garcia E; Lee EQ; Lin NU; Overmoyer B; Wen PY; Nayak L; Cohen JV; Dietrich J; Eichler A; Heist R; Krop I; Lawrence D; Ligibel J; Tolaney S; Mayer E; Winer E; Perrino CM; Summers EJ; Mahar M; Oh K; Shih HA; Cahill DP; Rosen BR; Yen YF; Kalpathy-Cramer J; Martinez-Lage M; Sullivan RJ; Brastianos PK; Emblem KE; Gerstner ER
    Neuro Oncol; 2024 May; 26(5):965-974. PubMed ID: 38070147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
    Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
    Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of patients with KRAS G12C mutated stage IV non-small cell lung cancer with and without brain metastases treated with immune checkpoint inhibitors.
    Swart EM; Noordhof AL; Damhuis RAM; Kunst PWA; De Ruysscher DKM; Hendriks LEL; van Geffen WH; Aarts MJ
    Lung Cancer; 2023 Aug; 182():107290. PubMed ID: 37419045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between systemic treatment with immune checkpoint inhibitor therapy in renal cell carcinoma and reduced risk of brain metastasis development.
    Damante M; Huntoon K; Gibbs D; Pezzutti D; Olencki T; Elder JB
    Neurosurg Focus; 2023 Aug; 55(2):E2. PubMed ID: 37527670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy.
    Hoffmann E; Gerwing M; Krähling T; Hansen U; Kronenberg K; Masthoff M; Geyer C; Höltke C; Wachsmuth L; Schinner R; Hoerr V; Heindel W; Karst U; Eisenblätter M; Maus B; Helfen A; Faber C; Wildgruber M
    Breast Cancer Res; 2023 May; 25(1):56. PubMed ID: 37221619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma.
    Lee HW
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34208157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues.
    Fan TW; Higashi RM; Song H; Daneshmandi S; Mahan AL; Purdom MS; Bocklage TJ; Pittman TA; He D; Wang C; Lane AN
    Elife; 2021 Aug; 10():. PubMed ID: 34406120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
    JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment.
    El Rassy E; Botticella A; Kattan J; Le Péchoux C; Besse B; Hendriks L
    Cancer Treat Rev; 2018 Jul; 68():69-79. PubMed ID: 29883857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy.
    Sun L; Davis CW; Hwang WT; Jeffries S; Sulyok LF; Marmarelis ME; Singh AP; Berman AT; Feigenberg SJ; Levin W; Ciunci CA; Bauml JM; Cohen RB; Langer CJ; Aggarwal C
    Clin Lung Cancer; 2021 Jan; 22(1):58-66.e3. PubMed ID: 33279417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study.
    Kawachi H; Tamiya M; Taniguchi Y; Yokoyama T; Yokoe S; Oya Y; Imaji M; Okabe F; Kanazu M; Sakata Y; Uematsu S; Tanaka S; Arai D; Saito G; Kobe H; Miyauchi E; Okada A; Hara S; Kumagai T
    JTO Clin Res Rep; 2022 Jul; 3(7):100355. PubMed ID: 35769388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases.
    Wei Y; Xu Y; Wang M
    Chin Med J (Engl); 2023 Jul; 136(13):1523-1531. PubMed ID: 37106555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
    Isomoto K; Haratani K; Tsujikawa T; Makutani Y; Kawakami H; Takeda M; Yonesaka K; Tanaka K; Iwasa T; Hayashi H; Ito A; Nishio K; Nakagawa K
    Lung Cancer; 2022 Dec; 174():71-82. PubMed ID: 36347190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    Kim R; Keam B; Kim S; Kim M; Kim SH; Kim JW; Kim YJ; Kim TM; Jeon YK; Kim DW; Chung DH; Lee JS; Heo DS
    BMC Cancer; 2019 Jan; 19(1):19. PubMed ID: 30616523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors.
    Hendriks LEL; Henon C; Auclin E; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Rabeau A; Le Moulec S; Cousin S; Duchemann B; le Pechoux C; Botticella A; Ammari S; Gazzah A; Caramella C; Adam J; Lechapt E; Planchard D; De Ruysscher D; Dingemans AM; Besse B
    J Thorac Oncol; 2019 Jul; 14(7):1244-1254. PubMed ID: 30780002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.
    Yi M; Jiao D; Qin S; Chu Q; Wu K; Li A
    Mol Cancer; 2019 Mar; 18(1):60. PubMed ID: 30925919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
    Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer.
    Mimura K; Shimomura A; Gota T; Ando K; Kawamura Y; Taniyama T; Oishi H; Shimizu C
    Gynecol Oncol Rep; 2022 Dec; 44():101084. PubMed ID: 36277029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.